TOVX — Theriva Biologics Share News
0.000.00%
Last trade - 00:00Brief: Theriva™ Biologics Announces Upcoming Presentation Of Additional Data From The Virage Phase 2B Clinical Trial Of Vcn-01 In Metastatic Pancreatic Cancer At Aacr 2026 Annual Meeting
Brief: Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications
Brief: Theriva Biologics Implements 32% Workforce Reduction - SEC Filing
Brief: Theriva™ Biologics Announces Presentation Of Data From Vcn-01 Retinoblastoma Phase 1 Clinical Trial At Asco 2025
Brief: Theriva Biologics Announces Pricing Of $7.5 Million Public Offering
Theriva Biologics soars after cancer drug meets main goal in mid-stage trial
Brief: Theriva Biologics Announces Primary Endpoints For Efficacy And Safety Achieved In VIRAGE Phase 2B Clinical Trial Of VCN-01 With Gemcitabine/NAB-Paclitaxel In Newly-Diagnosed Metastatic Pancreatic Cancer Patients
Brief: Theriva Biologics - European Commission Granted Orphan Medicinal Product Designation To VCN-01 For Treatment Of Retinoblastoma
Brief: Theriva Biologics Announces Orphan Medicinal Product Designation Granted By The European Commission To VCN-01 For The Treatment Of Retinoblastoma
Brief: Cvi Investments Inc. Reports 9.9% Passive Stake In Theriva Biologics Inc.
Brief: Theriva Biologics Announces Pricing Of $2.5 Mln Public Offering
Brief: Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
Brief: Theriva Biologics Announces Reverse Stock Split
Brief: Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer
Brief: Theriva Biologics Says Data For 9 Evaluable Patients Were Reviewed By Study Monitoring Committee Who Agreed Trial Had Positive Outcome
Brief: Theriva Biologics Announces Positive Recommendation On Phase 2B Trial Of Vcn-01 In Combination With Chemotherapy For Metastatic Pancreatic Ductal Adenocarcinoma
Brief: Theriva Biologics, Sant Joan de Déu-Barcelona Children’s Hospital to Explore Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer
Brief: Theriva Biologics Reports Second Quarter 2023 Operational Highlights And Financial Results
Brief: Theriva Biologics Announces Progress In Virage